LARIMAR THERAPEUTICS, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $47.9M | $40.8M | $39.9M | $54.6M | $27.4M | $9.6M | $11.5M |
| SG&A Expense | $13.2M | $12.2M | $18.3M | $19.2M | $8.1M | $4.2M | $2.2M |
| Operating Income | $-61.1M | $-53.0M | $-58.2M | $-73.8M | $-35.5M | $-13.8M | $-13.8M |
| Operating Margin | — | — | — | — | — | — | — |
| Interest Expense | $1.9M | $165.0K | $529.0K | $806.0K | $870.0K | — | $97.0K |
| Pretax Income | $-61.4M | $-52.0M | $-57.9M | $-74.3M | $-36.5M | $-14.0M | $-13.9M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-61.4M | $-52.0M | $-57.9M | $-74.3M | $-36.5M | $-14.0M | $-13.9M |
| Net Margin | — | — | — | — | — | — | — |
| EPS (Basic) | $-1.90 | $-1.90 | $-2.12 | $-2.78 | $-3.00 | $-19.53 | $-19.65 |
| EPS (Diluted) | $-1.90 | $-1.90 | $-2.12 | $-2.78 | $-3.00 | $-19.53 | $-19.65 |
| Shares Outstanding (Basic) | 37.3M | 27.5M | 27.3M | 27.2M | 22.9M | 729.4K | — |
| Shares Outstanding (Diluted) | 37.3M | 27.5M | 27.3M | 27.2M | 22.9M | 729.4K | — |
| Dividends Per Share | — | — | — | — | — | — | — |